{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:59Z","timestamp":1791919619109,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/bjc.2017.70","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T01:21:00Z","timestamp":1490145660000},"page":"1141-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy"],"prefix":"10.1038","volume":"116","author":[{"given":"Adi","family":"Nosrati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy K","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Tumeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain P","family":"Algazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Dan Linh","family":"Nguyen-Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Daud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"key":"BFbjc201770_CR1","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","volume":"64","author":"C Blank","year":"2004","unstructured":"Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF (2004) PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64: 1140\u20131145.","journal-title":"Cancer Res"},{"key":"BFbjc201770_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank CU, Haanen JB, Ribas A, Schumacher TN (2016) Cancer immunology. The \u2018cancer immunogram\u2019. Science 352: 658\u2013660.","journal-title":"Science"},{"key":"BFbjc201770_CR3","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, Mcmiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167\u20133175.","journal-title":"J Clin Oncol"},{"key":"BFbjc201770_CR4","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","volume":"126","author":"AI Daud","year":"2016","unstructured":"Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD (2016) Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 126: 3447\u20133452.","journal-title":"J Clin Invest"},{"key":"BFbjc201770_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED (2016) Pembrolizumab: a review in advanced melanoma. Drugs 76: 375\u2013386.","journal-title":"Drugs"},{"issue":"Suppl","key":"BFbjc201770_CR6","doi-asserted-by":"crossref","first-page":"abstr 9073","DOI":"10.1200\/jco.2013.31.15_suppl.9073","volume":"31","author":"RS Dronca","year":"2013","unstructured":"Dronca RS, Weaver A, Brewer JD, Shuster LT, Kottschade LA, Morita SY, Markovic S (2013) Gender differences in survival from cutaneous melanoma: analysis of United States SEER data, 1992 to 2009. J Clin Oncol 31 (Suppl): abstr 9073.","journal-title":"J Clin Oncol"},{"key":"BFbjc201770_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fonc.2015.00008","volume":"5","author":"RS Dronca","year":"2015","unstructured":"Dronca RS, Dong H (2015) A gender factor in shaping T-cell immunity to melanoma. Front Oncol 5: 8.","journal-title":"Front Oncol"},{"key":"BFbjc201770_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ni.2588","volume":"14","author":"JJ Goronzy","year":"2013","unstructured":"Goronzy JJ, Weyand CM (2013) Understanding immunosenescence to improve responses to vaccines. Nat Immunol 14: 428\u2013436.","journal-title":"Nat Immunol"},{"key":"BFbjc201770_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134\u2013144.","journal-title":"N Engl J Med"},{"key":"BFbjc201770_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, Mcdermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563\u2013567.","journal-title":"Nature"},{"key":"BFbjc201770_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s13566-015-0219-2","volume":"4","author":"SM Hiniker","year":"2015","unstructured":"Hiniker SM, Maecker HT, Knox SJ (2015) Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol 4: 339\u2013345.","journal-title":"J Radiat Oncol"},{"issue":"15_suppl","key":"BFbjc201770_CR12","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/jco.2014.32.15_suppl.3005","volume":"32","author":"Richard Kefford","year":"2014","unstructured":"Kefford R, RA, Hamid O, Robert C, Daud A, Wolchok JD (2014) Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstr 32(Suppl 5): 3005.","journal-title":"Journal of Clinical Oncology"},{"key":"BFbjc201770_CR13","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","volume":"18","author":"J Manola","year":"2000","unstructured":"Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18: 3782\u20133793.","journal-title":"J Clin Oncol"},{"key":"BFbjc201770_CR14","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22: 2908\u20132918.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201770_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE (2014) Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63: 247\u2013257.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbjc201770_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","volume":"45","author":"TF Nishijima","year":"2016","unstructured":"Nishijima TF, Muss HB, Shachar SS, Moschos SJ (2016) Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev 45: 30\u201337.","journal-title":"Cancer Treat Rev"},{"key":"BFbjc201770_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.abb.2014.06.018","volume":"563","author":"A Nosrati","year":"2014","unstructured":"Nosrati A, Wei ML (2014) Sex disparities in melanoma outcomes: the role of biology. Arch Biochem Biophys 563: 42\u201350.","journal-title":"Arch Biochem Biophys"},{"key":"BFbjc201770_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252\u2013264.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc201770_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.critrevonc.2010.06.012","volume":"75","author":"G Pawelec","year":"2010","unstructured":"Pawelec G, Derhovanessian E, Larbi A (2010) Immunosenescence and cancer. Crit Rev Oncol Hematol 75: 165\u2013172.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFbjc201770_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L (2016) Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44: 1255\u20131269.","journal-title":"Immunity"},{"key":"BFbjc201770_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/jnr.20881","volume":"84","author":"MJ Polanczyk","year":"2006","unstructured":"Polanczyk MJ, Hopke C, Vandenbark AA, Offner H (2006) Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 84: 370\u2013378.","journal-title":"J Neurosci Res"},{"key":"BFbjc201770_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/intimm\/dxl151","volume":"19","author":"MJ Polanczyk","year":"2007","unstructured":"Polanczyk MJ, Hopke C, Vandenbark AA, Offner H (2007) Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 19: 337\u2013343.","journal-title":"Int Immunol"},{"key":"BFbjc201770_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315: 1600\u20131609.","journal-title":"JAMA"},{"key":"BFbjc201770_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O\u2019day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16: 908\u2013918.","journal-title":"Lancet Oncol"},{"key":"BFbjc201770_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, Mcneil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320\u2013330.","journal-title":"N Engl J Med"},{"key":"BFbjc201770_CR26","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, Mcneil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521\u20132532.","journal-title":"N Engl J Med"},{"key":"BFbjc201770_CR27","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517\u20132526.","journal-title":"N Engl J Med"},{"key":"BFbjc201770_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.ai.2015.12.003","volume":"130","author":"S Spranger","year":"2016","unstructured":"Spranger S, Sivan A, Corrales L, Gajewski TF (2016) Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy. Adv Immunol 130: 75\u201393.","journal-title":"Adv Immunol"},{"key":"BFbjc201770_CR29","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1158\/1078-0432.CCR-13-2151","volume":"19","author":"RJ Sullivan","year":"2013","unstructured":"Sullivan RJ, Lorusso PM, Flaherty KT (2013) The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 19: 5283\u20135291.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201770_CR30","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20: 5064\u20135074.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201770_CR31","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, Mcmiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, Mcdonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443\u20132454.","journal-title":"N Engl J Med"},{"key":"BFbjc201770_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568\u2013571.","journal-title":"Nature"},{"key":"BFbjc201770_CR33","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","volume":"31","author":"JS Weber","year":"2013","unstructured":"Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31: 4311\u20134318.","journal-title":"J Clin Oncol"},{"issue":"22","key":"BFbjc201770_CR34","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kahler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank CU, Schadendorf D, Dummer R, Ascierto PA, Hospers GA, Garbe C, Wolchok JD (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22 (22): 5487\u20135496.","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201770","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.70","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:41:36Z","timestamp":1684417296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFbjc201770"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.70","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]},"assertion":[{"value":"19 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMG: Research funding from the Zurich University Hospital and received travel grant support from Novartis, Roche, MSD and BMS. He has an intermittent advisory board relationship with Novartis, Roche, MSD and BMS. PT: Founder and employee at Acteris. APA: Grants for clinical trial support from Merck, Bristol-Myers Squibb (BMS), Medimmune, AstraZeneca, Oncosec, Acerta, Novartis, and Glaxco SmithKline. RD: Research funding (Novartis, Merck and Co., Inc., Bristol-Myers Squibb, Roche, GlaxoSmithKline) and consultancy or advisory board (Novartis, Merck and Co., Inc., Bristol-Myers Squibb, Roche, GlaxoSmithKline, Amgen). OH: Consultancy (Amgen, Novartis, Roche, Bristol-Myers Squibb) and speaker (Bristol-Myers Squibb, Genentech, Novartis). AD: Advisory board: Merck Inc., Pfizer Inc., BMS Inc., Novartis, and Genentech Roche. Stock: OncoSec Inc. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}